Exposures, if they are mild, in the sense of barely just a small concentration, it's mostly an irritant, particularly the peroxides, that in that smoke would irritate the skin or even irritate the lungs. So, for the most time, it could be either just a little bit of a nuisance irritant, or if you get a really big whiff of it, particularly people who have, for example, reversible airways disease, like asthma or different types of hypersensitivity diseases, you could get a serious problem.

We feel confident that there won't be an outbreak.

We feel confident that there won't be an outbreak. The people who were around the patient are now being identified and traced by the CDC and by the state health authorities. ... you get people, you identify them, and you observe and monitor them daily to determine if they develop symptoms If they do, then you put them under isolation to determine if, in fact, they are infected. And if you do that properly, you can shut down any outbreak.

The launch of phase 1 Ebola vaccine studies is a first step in developing a vaccine that could be licensed and used in the field to protect not only the front line health care workers but also those living in areas where Ebola virus exists.

The nature of a protective immune response to HIV is still unclear. Because in a very, very unique manner, unlike virtually any other microbe with which we're familiar, the HIV virus has evolved in a way that the immune system finds it very difficult, if not impossible, to deal with the virus.

I believe I have a personal responsibility to make a positive impact on society.

Although it is still important to develop an HIV vaccine, we have significant tools already at our disposal that can make a major impact on the trajectory of this epidemic.